EA202191966A1 - Пентациклическое гетероциклическое соединение - Google Patents

Пентациклическое гетероциклическое соединение

Info

Publication number
EA202191966A1
EA202191966A1 EA202191966A EA202191966A EA202191966A1 EA 202191966 A1 EA202191966 A1 EA 202191966A1 EA 202191966 A EA202191966 A EA 202191966A EA 202191966 A EA202191966 A EA 202191966A EA 202191966 A1 EA202191966 A1 EA 202191966A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heterocyclic compound
pentacyclic heterocyclic
pentacyclic
xvii
formulas
Prior art date
Application number
EA202191966A
Other languages
English (en)
Inventor
Йосиаки ОХАСИ
Йосихико НОРИМИНЕ
Тамаки ХОСИКАВА
Ю Йосида
Йосихиса КОБАЯСИ
Нобухиро САТО
Кодзи Хагивара
Нобуаки Сато
Синсуке ХИРОТА
Такааки Харада
Хикару Йосимура
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of EA202191966A1 publication Critical patent/EA202191966A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Соединения, представленные формулами (I)-(XVII), или их фармацевтически приемлемые соли обладают активирующим действием в отношении холинергических нейронов и потенциально могут использоваться в качестве терапевтического средства для лечения когнитивной дисфункции.
EA202191966A 2019-03-05 2020-03-03 Пентациклическое гетероциклическое соединение EA202191966A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019039351 2019-03-05
PCT/JP2020/008881 WO2020179780A1 (ja) 2019-03-05 2020-03-03 五環式複素環化合物

Publications (1)

Publication Number Publication Date
EA202191966A1 true EA202191966A1 (ru) 2021-12-08

Family

ID=72336168

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191966A EA202191966A1 (ru) 2019-03-05 2020-03-03 Пентациклическое гетероциклическое соединение

Country Status (20)

Country Link
US (1) US11358972B2 (ru)
EP (1) EP3936190A4 (ru)
JP (1) JPWO2020179780A1 (ru)
KR (1) KR20210135224A (ru)
AR (1) AR118235A1 (ru)
AU (1) AU2020232044A1 (ru)
BR (1) BR112021015975A2 (ru)
CA (1) CA3129861A1 (ru)
CL (1) CL2021002144A1 (ru)
CO (1) CO2021010512A2 (ru)
EA (1) EA202191966A1 (ru)
IL (1) IL285511A (ru)
JO (1) JOP20210219A1 (ru)
MA (1) MA55221A (ru)
MX (1) MX2021009685A (ru)
PE (1) PE20211978A1 (ru)
SG (1) SG11202108780PA (ru)
TW (1) TWI821537B (ru)
WO (1) WO2020179780A1 (ru)
ZA (1) ZA202105729B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936189A4 (en) 2019-03-05 2022-12-14 Eisai R&D Management Co., Ltd. SALT OF A PENTACYCLIC COMPOUND AND CRYSTALS THEREOF

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE258234C (ru)
US4187306A (en) * 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
RU2117670C1 (ru) 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (ru) 1990-02-08 1993-01-01 Pfizer
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5736992A (en) * 1994-10-31 1998-04-07 Hewlett-Packard Pressure regulated free-ink ink-jet pen
KR100203456B1 (ko) * 1995-06-20 1999-06-15 한승수 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제
CL2004000348A1 (es) 1997-04-15 2005-01-14 Cephalon Inc & Kyowa Hakko Kog Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales.
CL2004000352A1 (es) 1998-05-26 2005-05-27 Cephalon Inc & Kyowa Hakko Kog Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales.
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
DE10246207B4 (de) * 2002-10-04 2008-04-03 Disetronic Licensing Ag Mikrodialysesonde mit spiralförmiger Leitung
US8252520B2 (en) 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
RU2007114763A (ru) 2004-10-20 2008-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) Галогенозамещенные производные бензодиазепинов
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
PL3680243T3 (pl) 2017-09-07 2022-02-14 Eisai R&D Management Co., Ltd. Związek pentacykliczny
EP3936189A4 (en) 2019-03-05 2022-12-14 Eisai R&D Management Co., Ltd. SALT OF A PENTACYCLIC COMPOUND AND CRYSTALS THEREOF

Also Published As

Publication number Publication date
BR112021015975A2 (pt) 2021-10-05
TW202100528A (zh) 2021-01-01
WO2020179780A1 (ja) 2020-09-10
KR20210135224A (ko) 2021-11-12
EP3936190A1 (en) 2022-01-12
JPWO2020179780A1 (ru) 2020-09-10
AU2020232044A1 (en) 2021-09-02
TWI821537B (zh) 2023-11-11
CA3129861A1 (en) 2020-09-10
EP3936190A4 (en) 2022-11-16
SG11202108780PA (en) 2021-09-29
CO2021010512A2 (es) 2021-10-29
ZA202105729B (en) 2022-08-31
MA55221A (fr) 2022-01-12
CN113453762A (zh) 2021-09-28
MX2021009685A (es) 2021-09-10
US11358972B2 (en) 2022-06-14
JOP20210219A1 (ar) 2023-01-30
US20200283452A1 (en) 2020-09-10
IL285511A (en) 2021-09-30
CL2021002144A1 (es) 2022-02-04
PE20211978A1 (es) 2021-10-05
AR118235A1 (es) 2021-09-22

Similar Documents

Publication Publication Date Title
JOP20220142A1 (ar) مثبطات kras g12c
PH12017502425A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
EA201991513A1 (ru) Производные пирана как ингибиторы cyp11a1 (цитохром p450 монооксигеназы 11a1)
EA202191519A1 (ru) Модуляторы trex1
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
PE20231651A1 (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2021007247A (es) Derivados de rapamicina.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
MX2021012105A (es) Compuestos de pirrol.
EA202191966A1 (ru) Пентациклическое гетероциклическое соединение
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
WO2023211684A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
MX2021014458A (es) Compuestos triciclicos.